Review article · 2016
Conference abstractPublished 20 Oct 2014
An old argument with a new paradigm
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Cardiovascular disease (CVD) is the leading cause of death in the U.S. for both men and women. Angiotensin II, through angiotensin type 1 receptor (AT1R), has a significant effect on cardiovascular dysfunction, making it a target for therapeutic intervention. Endogenous estrogen protects premenstrual women from cardiovascular disease; however, multiple clinical studies suggest otherwise. 2-methoxyestradiol (2ME2), a natural nontoxic metabolite of estrogen, has shown no significant physiological responses due to its low concentration and short half-life in circulation. Ongoing studies in our laboratory are focused on determining the pharmacological effect of 2ME2 on AT1R gene expression. In recent studies we examined the effects of 2ME2 on rat epithelial and vascular smooth muscle cells exposed for 24 hours and showed MAP Kinase mediated down-regulation of AT1R gene expression. 2ME2 was found to bind with high affinity to an endoplasmic reticulum membrane bound G-protein coupled receptor (GPR30) independent of classical nuclear estrogen receptors. GPR30 activation subsequently led to MAP Kinase activation through transactivation of an EGFR mediated pathway. This study provides the first evidence that 2ME2 is capable of altering AT1R gene expression. Furthermore, 2ME2 mediated down-regulatory effect on AT1R was correlated with reduced mean arterial blood pressure in spontaneously hypertensive rats. Because AT1R has a critical role in the control of CVD, 2ME2- induced changes in receptor expression may provide beneficial effects to the cardiovascular and other systems. This will further provide an indirect explanation for the premenopausal beneficial effects of estrogen.
Subjects
Diabetes & EndocrinologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 14 Jun 2018
Novel drug discovery approaches for cancer metabolism: old paradigm with new perspective
Editorial · 30 Apr 2025
Immune Reprogramming: A New Paradigm in Disease Treatment and Immunotherapy
Conference abstract · 2018
One health: A new paradigm in fighting infectious diseases in West Africa
Conference abstract · 17 Oct 2016
Towards a new paradigm in metabolism: The unsuspected intrinsic property of melanin to dissociate the water molecule
More from this journal
The newest in Endocrinology & Metabolic Syndrome.
Research article · 10 Apr 2025
Bibliometric Insights into Riboflavin's Impact on Sperm Quality and Fertility Research
Perspective · 22 Jan 2025
Stem Cells of Endocrine Organs in Normal Physiology and Disease
Perspective · 20 Jan 2025
An In-Depth Overview of Reproductive Endocrinology
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalEndocrinology & Metabolic Syndrome
- SubjectDiabetes & Endocrinology
- BylineArticles whose byline prints “Thomas Thekkumkara”

